SADDLE RIVER, N.J.--(BUSINESS WIRE)--PDI, Inc. (Nasdaq: PDII), a provider of commercialization services to the biopharmaceutical industry, today announced that it has signed an agreement with a top-10 pharmaceutical company for a new contract sales engagement for a cardiology drug. The initiative will utilize PDI’s exclusive Select Access team to reach primary care physicians and cardiologists. The contract, which will begin on April 2, 2007, is expected to generate approximately $13 million in revenue for PDI over its one-year term.
